Moderna price target lowered to $70 from $78 at UBS

UBS lowered the firm’s price target on Moderna (MRNA) to $70 from $78 and keeps a Buy rating on the shares. While there remain “uncertainties” in vaccines, the firm continues to see long-term value in oncology, the analyst tells investors in a research note.